Comparative Pharmacology
Head-to-head clinical analysis: ISOCAINE HYDROCHLORIDE versus LIDODERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOCAINE HYDROCHLORIDE versus LIDODERM.
ISOCAINE HYDROCHLORIDE vs LIDODERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isocaine hydrochloride is a local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and propagation of action potentials.
Lidocaine is an amide-type local anesthetic that blocks voltage-gated sodium channels (Nav1.7) in nerve cell membranes, inhibiting depolarization and conduction of nerve impulses, thereby producing both local anesthesia and systemic analgesia.
1-2% solution infiltrated subcutaneously or locally, maximum dose 4.5 mg/kg (with epinephrine) or 3.0 mg/kg (without epinephrine), not to exceed 300 mg.
Apply 1 to 3 patches (5% lidocaine) to intact skin over most painful area for up to 12 hours within a 24-hour period; maximum 3 patches at once.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5 hours in healthy adults. In patients with hepatic impairment, half-life may be prolonged to 6–8 hours; in severe renal impairment, half-life may extend to 4–6 hours.
Terminal elimination half-life is 3–5 hours after topical application; after intravenous administration, half-life is 1.5–2 hours. Clinical context: Systemic accumulation possible with prolonged use on inflamed skin.
Renal: Approximately 90% of the dose is excreted as metabolites (primarily conjugated with glucuronic acid) in urine. Fecal: About 10% eliminated unchanged or as metabolites in feces. Biliary excretion is negligible.
Renal excretion of metabolites (primarily 4-hydroxy-2,6-xylidine glucuronide) accounts for >85% of elimination; <3% excreted unchanged; biliary/fecal elimination minimal (<10%).
Category C
Category C
Local Anesthetic
Local Anesthetic